Moderna's COVID-19 vaccine generated $18 billion in peak revenue. The company has submitted a flu vaccine candidate to regulators, representing a potential new commercial opportunity but not yet approved. Approval and market uptake will determine the revenue impact; this could help diversify Moderna's product mix beyond its COVID franchise.
Moderna's COVID-19 vaccine generated $18 billion in peak revenue. The company has submitted a flu vaccine candidate to regulators, representing a potential new commercial opportunity but not yet approved. Approval and market uptake will determine the revenue impact; this could help diversify Moderna's product mix beyond its COVID franchise.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.12
Ticker Sentiment
